摘要
乳腺癌骨健康管理贯穿患者治疗的全周期。早期乳腺癌在辅助治疗过程中需要注意预防治疗引起的骨丢失,辅助应用骨改良药物则有助于改善部分患者的预后,而晚期骨转移患者应给予多学科综合治疗,并应用骨改良药物帮助预防骨相关不良事件。因此,无论早期还是晚期患者的治疗,都需要对骨健康给予重视,制定恰当的治疗策略,并处理好药物不良反应。良好的骨健康管理,将有助于改善患者的生活质量和生存。国家肿瘤质控中心乳腺癌专家委员会组织相关专家,基于循证医学证据,深入探讨乳腺癌骨健康的全周期管理,详细阐述了早期乳腺癌肿瘤治疗所致骨丢失的风险分级和治疗策略、辅助应用骨改良药物的适用人群和获益、晚期乳腺癌骨转移的诊疗以及骨改良药物不良反应的处理方法,为临床提供合理建议,以指导临床医师更好地应对临床中的骨健康问题。
Bone health management of breast cancer runs through the whole cycle of patient treatment.During the process of adjuvant treatment for early breast cancer,clinicians should be pay attention to the prevention of bone loss caused by treatment.Adjuvant use of bone-modifying agents can help improve the prognosis of some patients,and patients with bone metastases should be given multidisciplinary comprehensive treatment and use bone-modifying agents to prevent the occurrence bone related adverse events.Therefore,no matter for the treatment of early or advanced breast cancer,it is necessary to manage bone health,formulate appropriate treatment strategies,and deal with adverse events of drugs.Good bone health management will help improve the quality of life and survival of patients.The breast cancer expert committee of the National Cancer Quality Control Center organized relevant experts to deeply explore the full cycle management of bone health in breast cancer based on Evidence-based medicine evidence.The risk classification and treatment strategy of cancer treatment-induced bone loss in early breast cancer,the applicable population and benefits of adjuvant treatment of bone modifying drugs,the diagnosis and treatment of bone metastasis in advanced breast cancer,and the treatment of adverse reactions of bone modifying drugs were elaborated in detail.We hope to guide clinicians to better deal with bone health problems in clinical practice by putting forward reasonable suggestions for patients with breast cancer.
作者
国家肿瘤质控中心乳腺癌专家委员会
马飞
施秀青
Breast Cancer Expert Committee of National Caner Quality Control Center;Ma Fei(不详;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Caner/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021)
出处
《中华医学杂志》
CAS
CSCD
北大核心
2024年第2期107-124,共18页
National Medical Journal of China
基金
中国医学科学院医学与健康科技创新工程重大协同创新项目(2021-I2M-1-014)
关键词
乳腺肿瘤
骨健康
骨改良药物
Breast neoplasms
Bone health
Bone-modifying drug
作者简介
通信作者:马飞,国家癌症中心国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院肿瘤内科,北京100021,Email:drmafei@126.com
